AccuBio

25/05/2026

Decentralised care demands more than rapid results — it demands confidence in clinical decision-making.

AccuBio’s Fluorescence Immunoassays & Readers deliver quantitative testing at the point of care, supporting faster triage, improved workflow efficiency, and data-driven patient management across diverse healthcare settings.

As healthcare continues to shift closer to the patient, reliable quantitative diagnostics are becoming essential to modern decentralised care pathways.

Learn More: https://www.accubio.co.uk/products/analysers/FIA

21/05/2026

As recent events have demonstrated with hantavirus, access to reliable diagnostic tools remains important for supporting clinical and public health responses to outbreaks.

At AccuBio, we offer a professional use hantavirus test, which detects IgM antibodies to hantavirus, as part of our broader infectious disease portfolio.

Learn More: https://www.accubio.co.uk/products/infectiousdisease/vector-borne/hantavirus

20/05/2026

Last Thursday, AccuBio’s MHFA, Environmental and Social Committees came together to host a fantastic event in support of Mental Health Awareness Week 💚

From litter picking and green-themed activities to quizzes, snacks and prizes, the afternoon was a great reminder of the importance of wellbeing, teamwork and community spirit.

A huge thank you to everyone involved in organising the event and to all those who attended and took part. Events like these truly reflect one of AccuBio’s core values — Grow Together 🌱

Mental Health Foundation

15/05/2026

Reliable and robust sample collection devices are an essential part of point-of-collection screening for back-to-lab confirmatory testing.

AccuBio’s collection devices are designed to enable effective sample collection and transport, giving you confidence throughout the testing process.

Learn more: https://www.accubio.co.uk/products/toxicology/oral-fluid

07/05/2026

Point-of-collection substance misuse testing relies on rapid screening alongside robust, secure sample collection for back-to-lab confirmatory testing.

AccuBio offers rapid drugs of abuse testing as an on-site screening solutions alongside collection devices designed to provide secure transport for confirmatory laboratory analysis.

Learn more: https://www.accubio.co.uk/products/toxicology/oral-fluid

30/04/2026

Reliable, rapid malaria diagnostics improve early detection and disease management.

AccuBio's rapid malaria test range enable the differential detection of P. faliciparum, P. vivax and other (Pan) malarial species antigens and antibodies.

✅ Visual read
✅ Results in 20 minutes
✅ Use across decentralised settings

Learn more: https://www.accubio.co.uk/products/infectiousdisease/vector-borne/malaria

28/04/2026

Recent findings from the World Health Organization highlight that malaria remains a significant global health challenge, with an estimated 282 million cases reported in 2024.

While advances in prevention and treatment continue, sustaining progress depends on one critical factor: timely and accurate diagnosis.

Expanding access to reliable screening is essential—not only to support effective case management, but also to strengthen surveillance, guide treatment decisions, and limit further transmission.

As highlighted on World Malaria Day, progress is possible—but it requires consistent, coordinated action across the entire pathway, from detection to treatment.

https://www.who.int/publications/i/item/9789240117822

Addressing the threat of antimalarial drug resistance

25/04/2026

This : Grasp the moment.

Malaria continues to place a significant burden on global health, with hundreds of thousands of deaths reported each year.

Progress is being made through advances in vaccines, treatments and prevention strategies—but gains remain fragile. When efforts weaken, cases can rise quickly, reversing progress.

Early and accessible diagnostic screening remains a critical part of effective malaria control, supporting timely detection and response.

31/03/2026

From identifying nutrient deficiencies to diagnosing health conditions that impact metabolic processes.

AccuBio’s metabolism range supports the detection and monitoring of key biomarkers, including ferritin, vitamin D, vitamin B12 and thyroid function, for both self-testing and use in clinical settings.

Delivering accessible solutions to support health awareness and patient management.

Contact us: https://www.accubio.co.uk/contact.html

26/03/2026

Improving access to reliable Tuberculosis tests is key to reducing the global impact of TB infections.
AccuBio’s Tuberculosis IgM/IgG rapid lateral flow test provides a simple and accessible solution for detecting TB infections at the point of need.

• Results in 10 minutes
• Visual read
• Separate IgM and IgG results to indicate stage of infection

Supporting TB screening in decentralised healthcare settings.

Contact us: https://www.accubio.co.uk/products/infectiousdisease/respiratory/Tuberculosis

24/03/2026

Tuberculosis is the leading cause of death from a single infectious agent, globally.

This year’s campaign theme — “Yes! We can end TB!” — highlights the collective effort needed to prevent, diagnose and treat tuberculosis worldwide.

Near-point-of-care TB diagnostic testing is essential to close gaps in access to care.